ADRB2 and asthma: In two RCTs [34] conducted in parallel in patients with severe symptomatic asthma and treated with the add-on long-acting muscarinic antagonist (LAMA) tiotropium (TIO) 5 μg QD to ICS plus a long-acting β2-adrenoceptor (β2-AR) agonist (LABA), sex did not exert an influence on the improvement in peak FEV1, in the time to first severe asthma exacerbation, and in the time to first episode of asthma worsening vs. ICS/LABA.